Cell Therapy Strategy
Strategic Entry Points for New Cell Therapy Acquirers
For pharma and large biotech entering cell therapy for the first time, the choice between asset acquisition, platform deal, and manufacturing partnership shapes the next five years more than valuation does.
Three credible entry archetypes
Single-asset in-license with optionality; platform acquisition with retained founding team; and manufacturing/supply partnership as a learning vehicle before a larger transaction. Each implies a different internal build.
What the internal team needs to be ready for
Cell therapy is not a therapeutic area you can run from the existing oncology BD desk. New acquirers underestimate the technical operations and regulatory capability required to be a credible partner — sellers notice quickly.
Sequencing the first 24 months
A workable sequence: small co-development or option deal first; named internal owner with manufacturing experience; one larger transaction in year two once the team has seen a programme through real operational decisions.
For biotech partnering or asset strategy discussions, contact Kerlann Advisory.